Ann: Extension for Voluntary Suspension, page-23

Twelve reasons to look at Admedus
1) Admedus has commercialised important technology in the soft tissue repair space
2) Admedus is innovating around its manufacturing process for ADAPT®.
3) Admedus is growing sales of its ADAPT® products
4) Admedus is continuing to develop new products from ADAPT®.
5) Admedus has made significant progress on development of its TAVR product
6) Admedus has potential to partner with a major company on TAVR
7) Admedus has an established business distributing infusion systems in Australia
8) Admedus is moving towards overall profitability.
9) There is potential to realise value from Admedus’s DNA vaccine technologies
10) Admedus has a quality leadership team
11) Admedus has multiple physicians in the company
12) Admedus is undervalued, on our numbers

The above are the reasons put forward by NDF to encourage investors to take a position in AHZ. I would like to think that most of them are still relevant.